← Eichor
Study identifier: NCT06033144 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Prevalence of Tapia's Syndrome in Weaning Unit

Condition: Tapia's Syndrome  ·  Sponsor: Hopital Forcilles

PhaseN/A
Planned participants247
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Tapia syndrome is a rare and poorly understood pathology. It is defined by a concomitant attack of the recurrent (branch of X) and hypoglossal (XII) nerves of peripheral or central origin. It is characterized by the paralysis of a vocal cord and the ipsilateral half of tongue. This damage is most often unilateral but it can also be bilateral. It results in dysphonia and swallowing disorders. Tapia syndrome is a rare and poorly understood pathology. To date, less than 100 cases have been described in the literature. Previous works are mainly case reports and literature reviews. No prevalence study has been performed to date. Furthermore, disagreements persist regarding the semiology. Indeed, the involvement of the soft palate is not always described.

This description comes directly from the study's public registry record.

Talk to the study team

Estelle ROBIN, SLT  ·  01.60.64.62.41  ·  erobin@cognacq-jay.fr

Aymeric LE NEINDRE, Dr  ·  01.60.64.60.93  ·  aleneindre@cognacq-jay.fr

Always discuss trial participation with your own doctor first.

Locations (1)

Hôpital ForcillesFérolles-Attilly, Seine-et-Marne, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06033144